Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 10/20 | 0.42 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26530966 | 1.00 | LCK (0.42) | LCKATRMAPKAPK2CA12CA1 | |
| SCHEMBL30587255 | 0.92 | ATR (0.42) | LCKATRMAPKAPK2RORC | |
| SCHEMBL30587290 | 0.86 | LCK (0.34) | LCKATRMAPKAPK2 | |
| SCHEMBL26115151 | 0.83 | HDAC3 (0.36) | — | |
| SCHEMBL26118724 | 0.77 | ATR (0.51) | LCKATRCA12CA1CA9 | |
| SCHEMBL30587238 | 0.77 | ATR (0.51) | LCKATRCA12CA1CA9 | |
| SCHEMBL7816063 | 0.74 | LCK (0.42) | LCKATRCA12CA1CA9 | |
| SCHEMBL30587256 | 0.74 | CSNK2A2 (0.46) | — | |
| SCHEMBL26116037 | 0.74 | CSNK2A2 (0.46) | — | |
| SCHEMBL12902766 | 0.72 | ATR (0.45) | LCKATRMAPKAPK2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688792-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250289830-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2025-09-18 | — | — | US | disclosed |
| US-12351591-B2 | KRas inhibitors | ELI LILLY AND COMPANY (US) | 2025-07-08 | — | — | US | disclosed |
| EP-4499233-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20240368193-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-11-07 | — | — | US | disclosed |
| WO-2024206766-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2024-10-03 | — | — | WO | disclosed |
| US-20240043451-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-02-08 | — | — | US | disclosed |
| WO-2023183585-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043451-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | LCK 1059/4885ATR 1005/4885MAPKAPK2 1228/4885 |
| US-12351591-B2 | KRas inhibitors | KRAS, NRAS, HRAS | LCK 1059/4885ATR 1005/4885MAPKAPK2 1228/4885 |
| US-20240368193-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | LCK 601/4885ATR 945/4885MAPKAPK2 1383/4885 |
| US-20250289830-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | LCK 1059/4885ATR 1005/4885MAPKAPK2 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.